InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a.

Biotechnology

InflaRx

Niels C. Riedemann

Anja Pfaff

Michelle Medovich

Timothy E. Hermes

Daniel Vetter

Jacky Schmitt

Nicole Bertsch

Thomas Taapken

Renfeng Guo

Mark Kubler

Nicolas Fulpius

Tony Gibney

Richard Brudnick

Hege Hellstrom

The Research & Development team at InflaRx is responsible for advancing the company's pipeline of anti-C5a therapies through its stages from discovery to clinical application. This multidisciplinary team conducts preclinical research, drug discovery, pharmacovigilance, and clinical pharmacokinetics to ensure the safety, efficacy, and quality of new therapeutics aimed at treating inflammatory and autoimmune diseases.

Research & Development

This department manages and coordinates all clinical trials and research activities to ensure successful execution and compliance.

Clinical Operations

This department focuses on monitoring and evaluating the safety of pharmaceutical products to ensure patient safety and regulatory compliance.

Drug Safety

This department oversees the strategic direction and decision-making processes at the highest level of the organization.

Executive Governance

This department ensures that products meet required quality standards and regulatory compliance throughout the development process.

Quality Assurance

This department oversees and directs sales strategies and activities across regions.

InflaRx

Org chart

Board & advisors

Teams

Research & Development

Clinical Operations

Drug Safety

Executive Governance

Quality Assurance

Sales Management

Offices

InflaRx

Org chart

Board & advisors

Teams

Research & Development

Clinical Operations

Drug Safety

Executive Governance

Quality Assurance

Sales Management

Offices

Related companies